Stabilized Peptide Therapeutics (e.g., GLP-1)
Metabolic Disease
Pre-clinicalActive
Key Facts
About Constructive Bio
Constructive Bio is pioneering a dual-technology platform combining whole-genome synthesis and engineered translation to reprogram the genetic code of microorganisms. This enables the scalable, fermentation-based production of peptide and protein therapeutics containing precisely placed non-canonical amino acids, unlocking new chemistries and functions. The company is positioned to create next-generation drug candidates, such as stabilized GLP-1 analogs and site-specific antibody-drug conjugates, with potential advantages in stability, efficacy, and target engagement. Its foundational science is based on peer-reviewed research from Professor Jason Chin's lab.
View full company profileTherapeutic Areas
Other Metabolic Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| DVI-004 | Divamics | Preclinical |
| Undisclosed Peptide Programs | AmideBio | Preclinical |
| Undisclosed | Junevity | Pre-clinical |
| GLP‑1 Peptide Long‑Acting Injectable | Mapi Pharma | Preclinical |
| RZ-858 | Rezubio | Preclinical |